AbCellera Biologics (STU:8QQ) Gross-Profit-to-Asset % : 1.51% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is AbCellera Biologics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. AbCellera Biologics's annualized Gross Profit for the quarter that ended in Dec. 2024 was €19.29 Mil. AbCellera Biologics's average Total Assets over the quarter that ended in Dec. 2024 was €1,277.13 Mil. Therefore, AbCellera Biologics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 1.51%.

AbCellera Biologics Gross-Profit-to-Asset % Historical Data

The historical data trend for AbCellera Biologics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics Gross-Profit-to-Asset % Chart

AbCellera Biologics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

39.95

29.27

30.17

2.47

2.07

AbCellera Biologics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															2.42	2.70	2.05	1.83	1.51

Competitive Comparison of AbCellera Biologics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, AbCellera Biologics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AbCellera Biologics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where AbCellera Biologics's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

AbCellera Biologics Gross-Profit-to-Asset % Calculation

AbCellera Biologics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2024 )	/	( (Total Assets (A: Dec. 2023 )	+	Total Assets (A: Dec. 2024 ))	/ count )
	=	27.536	/	( (1364.582	+	1299.328)	/ 2 )
	=	27.536	/	1331.955
	=	2.07 %

AbCellera Biologics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	19.292	/	( (1254.938	+	1299.328)	/ 2 )
	=	19.292	/	1277.133
	=	1.51 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

AbCellera Biologics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

AbCellera Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (STU:8QQ) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

ABCL:USA 8QQ:Germany

Address

2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1

Website

https://www.abcellera.com

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

AbCellera Biologics Headlines

No Headlines